Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of “Moderate Buy” by Analysts

Altimmune, Inc. (NASDAQ:ALT) has earned a consensus rating of “Moderate Buy” from the ten research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $18.00.

A number of equities analysts have recently commented on ALT shares. Truist Financial started coverage on shares of Altimmune in a report on Wednesday, March 18th. They issued a “buy” rating and a $12.00 price target on the stock. HC Wainwright upped their target price on shares of Altimmune from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research note on Friday, March 27th. B. Riley Financial lowered their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Finally, Wall Street Zen lowered Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th.

Insider Buying and Selling at Altimmune

In other news, CEO Jerome Benedict Durso bought 20,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average price of $3.54 per share, for a total transaction of $70,800.00. Following the transaction, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at $115,050. This represents a 160.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders bought 30,000 shares of company stock worth $108,900. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Altimmune by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock worth $247,000 after acquiring an additional 2,241 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Altimmune during the 1st quarter valued at $50,000. Envestnet Asset Management Inc. raised its position in Altimmune by 48.0% in the 2nd quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company’s stock worth $127,000 after purchasing an additional 10,671 shares during the period. Geode Capital Management LLC raised its position in Altimmune by 13.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock worth $7,489,000 after purchasing an additional 228,995 shares during the period. Finally, Creative Planning lifted its stake in Altimmune by 30.2% in the second quarter. Creative Planning now owns 41,164 shares of the company’s stock worth $159,000 after purchasing an additional 9,558 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Stock Performance

Shares of ALT opened at $3.12 on Thursday. Altimmune has a 12-month low of $2.87 and a 12-month high of $7.73. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15. The company has a market cap of $405.91 million, a PE ratio of -3.09 and a beta of 0.34. The stock has a 50-day moving average price of $4.26 and a 200-day moving average price of $4.25.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.00 million. As a group, equities analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.